Navigation Links
Long-Term Data Show Advantages for TAXUS® Liberte® Stent in Small Vessels and Long Lesions
Date:9/22/2010

NATICK, Mass., Sept. 22 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS® Liberte® Paclitaxel-Eluting Stent System in a variety of lesions and patient groups.  Five-year results from the TAXUS ATLAS trial and four-year results from the TAXUS ATLAS Small Vessel and Long Lesion trials continue to show significant advantages for the thin-strut TAXUS Liberte Stent when compared to the first-generation TAXUS® Express® Stent.  Analysis of the data was presented by the Co-Principal Investigators of the TAXUS ATLAS trials, Mark A. Turco, M.D., Director of the Center for Cardiac and Vascular Research, Washington Adventist Hospital, and John A. Ormiston, M.D., Mercy Angiography Unit, Mercy Hospital, Auckland, New Zealand, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, D.C.  

"The TAXUS ATLAS trials continue to reinforce the long-term safety and efficacy of the TAXUS Liberte Stent in a variety of complex lesions," said Dr. Turco.  "The data showed sustained positive outcomes in workhorse lesions, significantly reduced rates of re-intervention in small vessels and important safety differences in long lesions.  The ATLAS data suggest that improvements in stent design and a reduction in strut thickness may contribute to improved clinical outcomes for patients treated with the TAXUS Liberte Stent."

TAXUS ATLAS "Workhorse" LesionsData from 871 patients in the TAXUS ATLAS trial demonstrated that the durable safety and efficacy profile of the TAXUS Liberte Stent is maintained at five years in de novo coronary ("workhorse") lesions.  In spite of more complex patients treated with the TAX
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... in the research, development and commercialization of prescription ophthalmic ... million advance from Hercules Technology Growth Capital, Inc. (NYSE: ... second and final advance under the Loan and Security ... Kingdom , Alimera Sciences Limited, entered into with ...
(Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
(Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Lifeinsurance-policy.com ... find the best life insurance prices for smokers. , ... life insurance premiums. Comparing quotes is the best method ... finding quotes for customers who need coverage. , ... entire duration of the policy. Since the coverage is ...
(Date:10/1/2014)... D.C. and ATLANTA (PRWEB) October 01, 2014 ... information security executive networking and relationship-marketing firm, ... 2014 Information Security Executive® and Project of ... include top-ranking decision makers representing organizations in ... academics. Projects include large-scale technology endeavors that ...
(Date:10/1/2014)... genetic finding from Duke Medicine suggests that some people ... also be hard-wired to gain weight when exposed to ... An estimated 13 percent of people, all of whom ... this could help them reduce heart disease with simple ... management. , "Genetic susceptibility, psychosocial stress and metabolic factors ...
(Date:10/1/2014)... 2014 Innovations announces the upcoming airing ... on Monday, October 20, 2014 at 7:30 a.m. EST/PT ... go behind the scenes to learn about Break the ... explore the practical help and information Break the Cycle ... warning signs of abuse, how to navigate the legal ...
Breaking Medicine News(10 mins):Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... high efficiency particle air (HEPA) filters along with ... cardiovascular health, according to researchers in Denmark. In ... filters for just two days significantly improved a ... elderly individuals. , Reduction of particle exposure by ...
... Calif., Feb. 15 Concentric Medical,Inc., the global leader ... announced the addition of Kimberly Bridges to its,management team ... a $15 million,line of credit., "We are delighted ... President and CEO of Concentric Medical. "Concentric is,entering a ...
... who showed that a single prostate specific antigen (PSA) test ... prostate cancer up to 25 years later, (regardless of clinical ... used to predict advanced prostate cancer. , The findings, ... help physicians identify which men would benefit from intensive screening. ...
... RUTHERFORD, N.J., Feb. 14 Cambrex,Corporation (NYSE: CBM ) reports ... 2007., (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), ... (-0.2% excluding foreign currency) compared to ... 6.7% (2.0% excluding foreign currency) compared to 2006. ...
... National Penn Bancshares Inc. (NASD:,NPBC) will replace Bradley Pharmaceuticals ... after the close of trading on Thursday, February 21, ... close on or about that date,pending final approvals., ... any relevant,updates on its website: http://www.standardandpoors.com ., ...
... The American people,through the U.S. Agency for ... program in Pakistan on child spacing and,reproductive health ... "FALAH is a visionary program that applies ... to deliver family planning services effectively and,explores new ...
Cached Medicine News:Health News:Using HEPA filters may improve cardiovascular health 2Health News:Early warning: PSA testing can predict advanced prostate cancer 2Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 2Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 3Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 4Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 5Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 6Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 7Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 8Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 9Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 10Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 11Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 12Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 13Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 14Health News:Standard & Poor's Announces Change to U.S. Index 2
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: